The legacy of Viagra and its impact on the pharmaceutical sector presents a complex question regarding its continued attractiveness as an investment. Initially a blockbuster success, generating huge sums , generic competition has significantly eroded earnings . While major pharmaceutical firms maintain patents on related therapies and develop new f

The trajectory of companies tied to flagship drugs like Viagra presents a challenging investment landscape . While the initial surge of copyright, fueled by Viagra's unprecedented popularity, generated substantial profits , the expiry in key markets has introduced substantial risk . Investors are now grappling with the impact of lower-cost alternat